BioInvent International Valuation Multiples

BioInvent International Overview

About BioInvent International

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

Founded

1996

HQ

Employees

112

Website

bioinvent.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $27M

EBITDA: ($35M)

EV

$96M

Valuation Multiples

Multiples.vc

Start free trial

BioInvent International Financials

BioInvent International reported last 12-month revenue of $27M and negative EBITDA of ($35M).

In the same LTM period, BioInvent International generated $26M in gross profit, ($35M) in EBITDA losses, and had net loss of ($35M).

BioInvent International P&L

In the most recent fiscal year, BioInvent International reported revenue of $25M and EBITDA of ($34M).

BioInvent International expects next 12-month revenue of XXX and NTM EBITDA of XXX

BioInvent International Stock Performance

BioInvent International has current market cap of $160M, and enterprise value of $96M.

BioInvent International's stock price is $2.43.

BioInvent International Valuation Multiples

BioInvent International trades at 3.6x EV/Revenue multiple, and (2.8x) EV/EBITDA.

BioInvent International Financial Valuation Multiples

As of April 18, 2026, BioInvent International has market cap of $160M and EV of $96M.

Equity research analysts estimate BioInvent International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

BioInvent International has a P/E ratio of (4.5x).

BioInvent International Margins & Growth Rates

BioInvent International's revenue in the last 12 month grew by 24%.

BioInvent International's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.6M for the same period.

BioInvent International's rule of 40 is (74%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

BioInvent International's rule of X is (38%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

BioInvent International Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

BioInvent International M&A Activity

BioInvent International acquired XXX companies to date.

Last acquisition by BioInvent International was on XXXXXXXX, XXXXX. BioInvent International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

BioInvent International Investment Activity

BioInvent International invested in XXX companies to date.

BioInvent International made its latest investment on XXXXXXXX, XXXXX. BioInvent International invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).